Hendrik-Tobias Arkenau


Dr Hendrik-Tobias Arkenau is the founding Medical Director of Sarah Cannon Research Institute UK, and is currently serving as the Executive Medical Director for SCRI UK and Clinical Lead for the Hospital Corporation of America International Cancer Service Line.

Dr Arkenau has vast experience in Early Oncology Clinical Drug Development with a special interest in gastrointestinal cancer and melanoma. He received his medical degree in 2000 at the Medical School Hanover, Germany, and completed his internship and specialist training in oncology in 2007. As part of SCRI’s collaboration with University College London (UCL), Dr Arkenau is appointed as a Professorial Research Associate on UCLs faculty and he holds an Honorary Consultant post with UCL Hospitals.

Sarah Cannon Research Institute UK’s remit is to incorporate all aspects of modern drug development from clinical pharmacology, molecular profiling to early clinical trials. The unique operational set-up aims to incorporate oncology drug development into day-to-day clinical practise with the ultimate goal to improve patient care.

Since its inauguration in 2010, Dr Arkenau has built up a trial portfolio of >80 early clinical trials. As Chief- and Principal Investigator he is actively involved in protocol development, toxicity review, pharmacokinetic analysis, biomarker and strategic development of new anti-cancer drugs, including immunotherapies. Dr Arkenau works as part of a multidisciplinary team of more than 40 members comprising of research nurses, operations specialist, project/data manager, regulatory adviser, QA-manager and other oncology specialists.

Dr Arkenau is Fellow of the Royal College of Physicians, and member of The German Cancer Society, ASCO, AACR and ESMO. He has presented multiple talks on the latest research in Oncology and has been Invited Speaker at several national/international meetings. Dr Arkenau has published articles in international peer-reviewed journals (e.g. Lancet, J Clin Oncol, Clin Cancer Res, Annals of Oncology and others) and serves as ‘Contributing Associate Editor-in-Chief’ of the World Journal of Gastroenterology and ‘Associate Editor’ of World Journal of Cancer Research.